FDA Approved: LOVAZA — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

The FDA approved a supplemental application for Lovaza (omega-3-acid ethyl esters), enabling changes to its labeling as requested by Waylis Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• LOVAZA (OMEGA-3-ACID ETHYL ESTERS)

Snippet

SUPPL AP for LOVAZA (OMEGA-3-ACID ETHYL ESTERS)